Hans‐Peter Gerber
Impact in
- Cancer Research top 0.1%
- Cancer, Hypoxia, and Metabolism
- Oncology top 0.2%
- HER2/EGFR in Cancer Research
- Cancer Cells and Metastasis
- Cancer Treatment and Pharmacology
Papers in
- Oncology 49
- HER2/EGFR in Cancer Research 23
- CAR-T cell therapy research 12
- Cancer Treatment and Pharmacology 6
-
- Angiogenesis and VEGF in Cancer 31
- Co-authors
- Napoleone Ferrara (34 shared papers)Jennifer LeCouter (2 shared papers)Kenneth J. Hillan (3 shared papers)William Novotny (1 shared paper)Vishva M. Dixit (1 shared paper)Ajay K. Malik (6 shared papers)Xiao Liang (5 shared papers)Fabrizio Condorelli (1 shared paper)
- Journals
- Cancer Research (9 papers)Molecular Cancer Therapeutics (9 papers)Blood (7 papers)mAbs (5 papers)Journal of Biological Chemistry (5 papers)
- Partner nations
- United StatesSwitzerlandFrance
In The Last Decade
Hans‐Peter Gerber
89 papers receiving 20.5k citations
Hans‐Peter Gerber's Hit Papers
Peers
Comparison fields: 5 of 155
- Cancer Research 4.6k
- Oncology 5.7k
- Molecular Biology 12.1k
- Immunology and Allergy 757
- Genetics 1.3k
Countries citing papers authored by Hans‐Peter Gerber
This map shows the geographic impact of Hans‐Peter Gerber's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hans‐Peter Gerber with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hans‐Peter Gerber more than expected).
Fields of papers citing papers by Hans‐Peter Gerber
This network shows the impact of papers produced by Hans‐Peter Gerber. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hans‐Peter Gerber. The network helps show where Hans‐Peter Gerber may publish in the future.
Co-authors
The 25 scholars most cited alongside Hans‐Peter Gerber, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 91 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | The biology of VEGF and its receptors Hit paper breakdown → | 2003 | 7641 |
| 2 | Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Hit paper breakdown → | 2004 | 2007 |
| 3 | Vascular Endothelial Growth Factor Induces Expression of the Antiapoptotic Proteins Bcl-2 and A1 in Vascular Endothelial Cells Hit paper breakdown → | 1998 | 782 |
| 4 | VEGF is required for growth and survival in neonatal mice Hit paper breakdown → | 1999 | 727 |
| 5 | Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells Hit paper breakdown → | 2007 | 673 |
| 6 | Differential Transcriptional Regulation of the Two Vascular Endothelial Growth Factor Receptor Genes Hit paper breakdown → | 1997 | 642 |
| 7 | VEGF regulates haematopoietic stem cell survival by an internal autocrine loop mechanism Hit paper breakdown → | 2002 | 567 |
| 8 | Angiogenesis-Independent Endothelial Protection of Liver: Role of VEGFR-1 Hit paper breakdown → | 2003 | 513 |
| 9 | Transcriptional Activation Modulated by Homopolymeric Glutamine and Proline Stretches Hit paper breakdown → | 1994 | 510 |
| 10 | 2005 | 492 | |
| 11 | 2004 | 446 | |
| 12 | 2006 | 418 | |
| 13 | 2001 | 349 | |
| 14 | 2002 | 306 | |
| 15 | 2001 | 300 | |
| 16 | 2005 | 282 | |
| 17 | 2004 | 228 | |
| 18 | 2002 | 205 | |
| 19 | Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. | 2000 | 200 |
| 20 | 2005 | 191 |
About Hans‐Peter Gerber
Hans‐Peter Gerber is a scholar working on Oncology, Molecular Biology, Radiology, Nuclear Medicine and Imaging, Cancer Research and Immunology, having authored 91 papers that have together received 21.1k indexed citations. Recurring topics across this work include Monoclonal and Polyclonal Antibodies Research (31 papers), Angiogenesis and VEGF in Cancer (31 papers), HER2/EGFR in Cancer Research (23 papers), Cancer, Hypoxia, and Metabolism (14 papers), CAR-T cell therapy research (12 papers), Cell Adhesion Molecules Research (8 papers), Lymphoma Diagnosis and Treatment (7 papers) and Cancer Treatment and Pharmacology (6 papers). The work is most often cited by research in Cancer Research (4.6k citations), Oncology (5.7k citations), Molecular Biology (12.1k citations), Immunology and Allergy (757 citations) and Genetics (1.3k citations). Hans‐Peter Gerber has collaborated with scholars based in United States, Switzerland and France. Frequent co-authors include Napoleone Ferrara, Jennifer LeCouter, Kenneth J. Hillan, William Novotny, Vishva M. Dixit, Ajay K. Malik, Xiao Liang, Fabrizio Condorelli, Jeanie Park and Joe Kowalski. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Blood, mAbs and Journal of Biological Chemistry.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.